{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:27:24Z","timestamp":1791239244367,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>The aim of our study was to explore predictive factors associated with compete biochemical response (CBR) in primary biliary cholangitis (PBC) patients treated with ursodeoxycholic acid (UDCA) at month 12 and at last check-up; CBR was defined as both normal bilirubin and ALP levels. We also evaluated hepatic decompensation and prognosis during UDCA treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a multicenter retrospective study of PBC patients. We enrolled patients with PBC before the beginning of UDCA treatment (13\u201315\u00a0mg\/kg body weight per day) between 1999 and 2024 in 2 hepatology centers in Eastern Slovakia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We enrolled 155 patients in the final analysis, 147 women and 8 men, mean age at diagnosis 57\u2009\u00b1\u200915 years, the median follow-up was 10\u2009\u00b1\u20098 years. 29 patients (18.7%) had cirrhosis at diagnosis. Hepatic decompensation occurred in 12 patients during follow-up (7.7%; 95%CI 4\u201313%). 114 patients (73.5%; 95% CI 66\u201380%) achieved response to treatment according to Toronto criteria at month 6; CBR after 12 months of treatment was achieved by 41.3% (95% CI 33\u201350%) of patients; 51 patients (32.9%; 95% CI 26\u201341%) achieved CBR at last check-up. The OR for achieving CBR at month 12 in Toronto responders at month 6 was 46.36 (95%CI 6.147-349.646);\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001. Of the patients who achieved a response defined by Toronto criteria at month 6, 44.7% of patients achieved CBR at last check-up and 55.3% did not. Out of the patients who did not achieve Toronto at month 6, none achieved CBR at last check-up (0%). Treatment response by Toronto criteria at month 6, CBR at month 12 and absence of liver cirrhosis predicted CBR at last check-up. The odds of decompensation were about 90% lower in patients who achieved treatment response. No case of hepatic decompensation or liver-related mortality during follow-up was observed in patients with CBR at last check-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The assessment of treatment response at month 6 is very accurate predictor of complete biochemical response throughout the course of the disease. For non-responders to UDCA treatment, the addition of second line PBC treatment is indicated. For patients who have not met Toronto criteria at month 6 of UDCA treatment, the addition of second line PBC therapy should be considered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-025-04138-w","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T18:33:47Z","timestamp":1754764427000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Early assessment of treatment response in primary biliary cholangitis: key to timely management"],"prefix":"10.1186","volume":"25","author":[{"given":"Tomas","family":"Koky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Drazilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Janicko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika","family":"Toporcerova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Gazda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Jarcuska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,9]]},"reference":[{"issue":"1","key":"4138_CR1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. Electronic address eee, European association for the study of the L: EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145\u201372.","journal-title":"J Hepatol"},{"issue":"4","key":"4138_CR2","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/hep.32117","volume":"75","author":"KD Lindor","year":"2022","unstructured":"Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2021 practice guidance update from the American association for the study of liver diseases. Hepatology. 2022;75(4):1012\u20133.","journal-title":"Hepatology"},{"key":"4138_CR3","doi-asserted-by":"publisher","first-page":"9151525","DOI":"10.1155\/2021\/9151525","volume":"2021","author":"J Gazda","year":"2021","unstructured":"Gazda J, Drazilova S, Janicko M, Jarcuska P. The Epidemiology of Primary Biliary Cholangitis in European Countries: A Systematic Review and Meta-Analysis. Can J Gastroenterol Hepatol. 2021;2021:9151525.","journal-title":"Can J Gastroenterol Hepatol."},{"issue":"4","key":"4138_CR4","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1136\/gut.46.4.553","volume":"46","author":"L Muratori","year":"2000","unstructured":"Muratori L, Parola M, Ripalti A, Robino G, Muratori P, Bellomo G, Carini R, Lenzi M, Landini MP, Albano E, et al. Liver\/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane. Gut. 2000;46(4):553\u201361.","journal-title":"Gut"},{"issue":"11\u201312","key":"4138_CR5","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1111\/j.1365-2036.2006.03172.x","volume":"24","author":"A Granito","year":"2006","unstructured":"Granito A, Muratori P, Muratori L, Pappas G, Cassani F, Worthington J, Guidi M, Ferri S, C DEM, Lenzi M, et al. Antinuclear antibodies giving the \u2018multiple nuclear dots\u2019 or the \u2018rim-like\/membranous\u2019 patterns: diagnostic accuracy for primary biliary cirrhosis. Aliment Pharmacol Ther. 2006;24(11\u201312):1575\u201383.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"4138_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1586\/erm.11.82","volume":"12","author":"A Granito","year":"2012","unstructured":"Granito A, Muratori P, Quarneti C, Pappas G, Cicola R, Muratori L. Antinuclear antibodies as ancillary markers in primary biliary cirrhosis. Expert Rev Mol Diagn. 2012;12(1):65\u201374.","journal-title":"Expert Rev Mol Diagn"},{"issue":"1","key":"4138_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/ajg.2009.596","volume":"105","author":"A Granito","year":"2010","unstructured":"Granito A, Yang WH, Muratori L, Lim MJ, Nakajima A, Ferri S, Pappas G, Quarneti C, Bianchi FB, Bloch DB, et al. PML nuclear body component Sp140 is a novel autoantigen in primary biliary cirrhosis. Am J Gastroenterol. 2010;105(1):125\u201331.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"4138_CR8","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jhep.2010.09.002","volume":"54","author":"KM Boberg","year":"2011","unstructured":"Boberg KM, Chapman RW, Hirschfield GM, Lohse AW, Manns MP, Schrumpf E, International Autoimmune Hepatitis G. Overlap syndromes: the international autoimmune hepatitis group (IAIHG) position statement on a controversial issue. J Hepatol. 2011;54(2):374\u201385.","journal-title":"J Hepatol"},{"issue":"5","key":"4138_CR9","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1002\/hep.22825","volume":"49","author":"P Muratori","year":"2009","unstructured":"Muratori P, Granito A, Pappas G, Muratori L. Validation of simplified diagnostic criteria for autoimmune hepatitis in Italian patients. Hepatology. 2009;49(5):1782\u20133. author reply 1783.","journal-title":"Hepatology"},{"issue":"2","key":"4138_CR10","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3390\/gastroent15020030","volume":"15","author":"S Drazilova","year":"2024","unstructured":"Drazilova S, Koky T, Macej M, Janicko M, Simkova D, Tsedendamba A, Komarova S, Jarcuska P. Pruritus, fatigue, osteoporosis and dyslipoproteinemia in Pbc patients: A clinician\u2019s perspective. Gastroenterol Insights. 2024;15(2):419\u201332.","journal-title":"Gastroenterol Insights"},{"key":"4138_CR11","doi-asserted-by":"publisher","unstructured":"Gazda J, Drazilova S, Gazda M, Janicko M, Koky T, Macej M, Carbone M, Jarcuska P. Treatment response to ursodeoxycholic acid in primary biliary cholangitis: A systematic review and meta-analysis. Dig Liver Dis. 2022. https:\/\/doi.org\/10.1016\/j.dld.2022.12.010.","DOI":"10.1016\/j.dld.2022.12.010"},{"key":"4138_CR12","doi-asserted-by":"publisher","unstructured":"Gazda J, Drazilova S, Janicko M, Grgurevic I, Filipec Kanizaj T, Koller T, Bodorovska B, Bozin T, Mijic M, Rob Z, et al. Prognostic factors in primary biliary cholangitis: A retrospective study of joint Slovak and Croatian cohort of 249 patients. J Pers Med. 2021;11(6). https:\/\/doi.org\/10.3390\/jpm11060495.","DOI":"10.3390\/jpm11060495"},{"issue":"2","key":"4138_CR13","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","volume":"71","author":"MH Harms","year":"2019","unstructured":"Harms MH, van Buuren HR, Corpechot C, Thorburn D, Janssen HLA, Lindor KD, Hirschfield GM, Pares A, Floreani A, Mayo MJ, et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. J Hepatol. 2019;71(2):357\u201365.","journal-title":"J Hepatol"},{"issue":"2","key":"4138_CR14","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jhep.2022.10.007","volume":"78","author":"F Nevens","year":"2023","unstructured":"Nevens F, Trauner M, Manns MP. Primary biliary cholangitis as a roadmap for the development of novel treatments for cholestatic liver diseases(dagger). J Hepatol. 2023;78(2):430\u201341.","journal-title":"J Hepatol"},{"issue":"10","key":"4138_CR15","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1038\/ajg.2010.216","volume":"105","author":"T Kumagi","year":"2010","unstructured":"Kumagi T, Guindi M, Fischer SE, Arenovich T, Abdalian R, Coltescu C, Heathcote EJ, Hirschfield GM. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol. 2010;105(10):2186\u201394.","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"4138_CR16","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.14309\/ajg.0000000000000557","volume":"115","author":"CF Murillo Perez","year":"2020","unstructured":"Murillo Perez CF, Harms MH, Lindor KD, van Buuren HR, Hirschfield GM, Corpechot C, van der Meer AJ, Feld JJ, Gulamhusein A, Lammers WJ, et al. Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase. Am J Gastroenterol. 2020;115(7):1066\u201374.","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"4138_CR17","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMoa1509840","volume":"375","author":"F Nevens","year":"2016","unstructured":"Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, Drenth JP, Pockros PJ, Regula J, Beuers U, et al. A Placebo-Controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375(7):631\u201343.","journal-title":"N Engl J Med"},{"issue":"5","key":"4138_CR18","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.cgh.2019.09.050","volume":"18","author":"CL Bowlus","year":"2020","unstructured":"Bowlus CL, Pockros PJ, Kremer AE, Pares A, Forman LM, Drenth JPH, Ryder SD, Terracciano L, Jin Y, Liberman A, et al. Long-Term obeticholic acid therapy improves histological endpoints in patients with primary biliary cholangitis. Clin Gastroenterol Hepatol. 2020;18(5):1170\u20138. e1176.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"4138_CR19","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S2468-1253(19)30094-9","volume":"4","author":"M Trauner","year":"2019","unstructured":"Trauner M, Nevens F, Shiffman ML, Drenth JPH, Bowlus CL, Vargas V, Andreone P, Hirschfield GM, Pencek R, Malecha ES, et al. Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. Lancet Gastroenterol Hepatol. 2019;4(6):445\u201353.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"4138_CR20","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1111\/liv.15379","volume":"42","author":"MC Londono","year":"2022","unstructured":"Londono MC, Diaz-Gonzalez A. Predicting liver-related serious adverse events in patients with primary biliary cholangitis-related cirrhosis treated with obeticholic acid. Liver Int. 2022;42(11):2356\u20139.","journal-title":"Liver Int"},{"key":"4138_CR21","doi-asserted-by":"publisher","unstructured":"Kowdley KV, Hirschfield GM, Coombs C, Malecha ES, Bessonova L, Li J, Rathnayaka N, Mells G, Jones DE, Trivedi PJ, et al. COBALT: A confirmatory trial of obeticholic acid in primary biliary cholangitis with placebo and external controls. Am J Gastroenterol. 2024. https:\/\/doi.org\/10.14309\/ajg.0000000000003029.","DOI":"10.14309\/ajg.0000000000003029"},{"issue":"23","key":"4138_CR22","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","volume":"378","author":"C Corpechot","year":"2018","unstructured":"Corpechot C, Chazouilleres O, Rousseau A, Le Gruyer A, Habersetzer F, Mathurin P, Goria O, Potier P, Minello A, Silvain C, et al. A Placebo-Controlled trial of Bezafibrate in primary biliary cholangitis. N Engl J Med. 2018;378(23):2171\u201381.","journal-title":"N Engl J Med"},{"key":"4138_CR23","doi-asserted-by":"publisher","first-page":"818089","DOI":"10.3389\/fphar.2021.818089","volume":"12","author":"GGL Cancado","year":"2021","unstructured":"Cancado GGL, Couto CA, Guedes LV, Braga MH, Terrabuio DRB, Cancado ELR, Ferraz MLG, Villela-Nogueira CA, Nardelli MJ, Faria LC, et al. Fibrates for the treatment of primary biliary cholangitis unresponsive to ursodeoxycholic acid: an exploratory study. Front Pharmacol. 2021;12:818089.","journal-title":"Front Pharmacol"},{"key":"4138_CR24","doi-asserted-by":"publisher","first-page":"204062232211141","DOI":"10.1177\/20406223221114198","volume":"13","author":"C Li","year":"2022","unstructured":"Li C, Zheng K, Chen Y, He C, Liu S, Yang Y, Li M, Zeng X, Wang L, Zhang F. A randomized, controlled trial on Fenofibrate in primary biliary cholangitis patients with incomplete response to ursodeoxycholic acid. Ther Adv Chronic Dis. 2022;13:20406223221114198.","journal-title":"Ther Adv Chronic Dis"},{"issue":"2","key":"4138_CR25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jhep.2020.09.011","volume":"74","author":"GM Hirschfield","year":"2021","unstructured":"Hirschfield GM, Beuers U, Kupcinskas L, Ott P, Bergquist A, Farkkila M, Manns MP, Pares A, Spengler U, Stiess M, et al. A placebo-controlled randomised trial of Budesonide for PBC following an insufficient response to UDCA. J Hepatol. 2021;74(2):321\u20139.","journal-title":"J Hepatol"},{"key":"4138_CR26","doi-asserted-by":"crossref","unstructured":"Hirschfield GM, Bowlus CL, Mayo MJ, Kremer AE, Vierling JM, Kowdley KV, Levy C, Villamil A, Ladron de Guevara Cetina AL, Janczewska E et al. A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis. N Engl J Med. 2024;390(9):783\u2013794.","DOI":"10.1056\/NEJMoa2312100"},{"issue":"9","key":"4138_CR27","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2306185","volume":"390","author":"KV Kowdley","year":"2024","unstructured":"Kowdley KV, Bowlus CL, Levy C, Akarca US, Alvares-da-Silva MR, Andreone P, Arrese M, Corpechot C, Francque SM, Heneghan MA, et al. Efficacy and safety of Elafibranor in primary biliary cholangitis. N Engl J Med. 2024;390(9):795\u2013805.","journal-title":"N Engl J Med"},{"issue":"1","key":"4138_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jhep.2021.08.025","volume":"76","author":"R Vuppalanchi","year":"2022","unstructured":"Vuppalanchi R, Caldwell SH, Pyrsopoulos N, deLemos AS, Rossi S, Levy C, Goldberg DS, Mena EA, Sheikh A, Ravinuthala R, et al. Proof-of-concept study to evaluate the safety and efficacy of Saroglitazar in patients with primary biliary cholangitis. J Hepatol. 2022;76(1):75\u201385.","journal-title":"J Hepatol"},{"issue":"9","key":"4138_CR29","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/hep4.1209","volume":"2","author":"MJ Mayo","year":"2018","unstructured":"Mayo MJ, Wigg AJ, Leggett BA, Arnold H, Thompson AJ, Weltman M, Carey EJ, Muir AJ, Ling L, Rossi SJ, et al. NGM282 for treatment of patients with primary biliary cholangitis: A multicenter, randomized, Double-Blind, Placebo-Controlled trial. Hepatol Commun. 2018;2(9):1037\u201350.","journal-title":"Hepatol Commun"},{"issue":"1","key":"4138_CR30","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s12072-022-10431-7","volume":"17","author":"C Yang","year":"2023","unstructured":"Yang C, Guo G, Li B, Zheng L, Sun R, Wang X, Deng J, Jia G, Zhou X, Cui L, et al. Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion. Hepatol Int. 2023;17(1):237\u201348.","journal-title":"Hepatol Int"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04138-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04138-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04138-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T22:40:08Z","timestamp":1757371208000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-04138-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,9]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4138"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04138-w","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,9]]},"assertion":[{"value":"20 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol is in accordance with the 1964 Helsinki declaration, its later amendments, and the principles of good clinical practice. The study protocol was approved by the Ethical committee of Poprad Hospital, a.s. on 5 May 2019 and by Ethical committee of L Pasteur University Hospital on 22 October 2020. The committee waived the need for the specific patients. informed consent due to the retrospective nature of the data collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"571"}}